As of 5 January 2023, the French health authority, Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), has suspended marketing authorisations for two drugs in accordance with an earlier decision by the European Medicines Agency (EMA). The drugs are Zolmitriptan Mylan (2.5 mg orodispersible or film-coated...
France suspends marketing authorisation for migraine and HIV drugs
Heather Mason
 | Â
Medical News
 | Â
23 January 2023
Register or log in to read more
Registration is free and easy, giving you complete access to all Univadis content.
Create a Free Account I have an account
         Â